Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Return on Sales (2016 - 2026)

Myriad Genetics has reported Return on Sales over the past 17 years, most recently at 0.0% for Q4 2025.

  • Quarterly Return on Sales changed 0.0% to 0.0% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.0% through Dec 2025, changed 0.0% year-over-year, with the annual reading at 0.0% for FY2025, 0.0% changed from the prior year.
  • Return on Sales was 0.0% for Q4 2025 at Myriad Genetics, up from 0.0% in the prior quarter.
  • Over five years, Return on Sales peaked at 0.0% in Q3 2021 and troughed at 0.02% in Q2 2025.
  • The 5-year median for Return on Sales is 0.0% (2025), against an average of 0.0%.
  • Year-over-year, Return on Sales rose 1bps in 2021 and then decreased -1bps in 2023.
  • A 5-year view of Return on Sales shows it stood at 0.0% in 2021, then plummeted by -403bps to 0.0% in 2022, then surged by 33bps to 0.0% in 2023, then fell by -27bps to 0.0% in 2024, then soared by 81bps to 0.0% in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Return on Sales are 0.0% (Q4 2025), 0.0% (Q3 2025), and 0.02% (Q2 2025).